Exploring PsA & Reproductive Health: Case by Case
PsARepro-EXP24
Seronegative Spondyloarthropathies
Sunday, August 1, 2021, 12:00 AM
Thursday, August 1, 2024, 11:55 PM
CME, MOC, Participation
1.00
1.00
Rheumatologists, Primary Care Physicians, OB-GYNs, Advanced Practice Nurses, Physician Assistants

Activity Information

Grounded in the 2020 American College of Rheumatology Guideline for Reproductive Health in Rheumatic and Musculoskeletal Diseases, this activity will increase learners' knowledge about best practices for patients with Psoriatic Arthritis (PsA) who are navigating various stages of their reproductive health journey.


Target Audience

Prescribing providers working with patients of reproductive age with rheumatic disease, including rheumatologists, rheumatology PAs/NPs, OB-GYNs, family medicine practitioners, and more.


Learning Objectives

Upon completion of this activity, participants should be able to do the following:

  • Discuss at least two effects of Psoriatic Arthritis (PsA) on pregnancy
  • Explain potential adverse pregnancy outcomes associated with PsA
  • List at least three impacts of drugs used in the treatment of PsA during pregnancy and lactation
  • Demonstrate successful use and integration of the ACR Reproductive Health in Rheumatic Diseases guidelines into patient care through case studies


Registration Fees

Registration is complimentary.


CME and MOC Information

Accreditation Statement

The American College of Rheumatology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement

The ACR designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activities.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

By completing this activity you provide the ACR permission to share completion data with the ACCME and the certifying board(s).


cme/moc


Faculty and Disclosures

ACR Disclosure Statement

It is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners' and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org.

Nature of Financial Relationships

Faculty participating in an ACR-sponsored activity must disclose to the planning committee and audience all financial relationships with ineligible companies any financial or other relationship(s) with a ineligible company including, but not limited to:

  1. Advisor or review panel member
  2. Consultant
  3. Employee
  4. Officer or Board Member
  5. Grant/research support
  6. Speaker/honoraria includes speakers bureau, symposia, and expert witness
  7. Independent contractor
  8. Ownership Interest
  9. Royalties
  10. Intellectual property/patents
  11. Stock options or bond holdings in a for-profit corporation or self-directed pension plan
  12. Other financial or material support

None: Has no relevant financial relationship(s) with ineligible companies to disclose.

Planning Committee

The following planning committee members have no relevant financial relationship(s) with ineligible companies to disclose.

  • Sonam Kiwalkar, MD
  • Vagishwari Murugesan, MC
  • Mehret Birru Talabi, MD

The following planning committee members have relevant financial relationship(s) with ineligible companies to disclose.

  • Linda Grinnell-Merrick, NP-BC – Novartis2,6, Abbvie2,6, Amgen6, UCB2, Pfizer2, Sanofi/Avion Phar2,6
  • Arthur Kavanaugh, MD – Amgen7, Abbvie7, Janssen7, Novartis7, Pfizer7, UCB7

Faculty

The following faculty members have no relevant financial relationship(s) with ineligible companies to disclose.

  • Sonam Kiwalkar, MD
  • Vagishwari Murugesan, MC
  • Mehret Birru Talabi, MD

The following faculty members have relevant financial relationship(s) with ineligible companies to disclose.

  • Linda Grinnell-Merrick, NP-BC – Novartis2,6, Abbvie2,6, Amgen6, UCB2, Pfizer2, Sanofi/Avion Phar2,6
  • Arthur Kavanaugh, MD – Amgen7, Abbvie7, Janssen7, Novartis7, Pfizer7, UCB7

*All of the relevant financial relationships listed for these individuals have been mitigated.


Acknowledgement of Support

These educational materials were supported by a medical education grant from Pfizer, Inc. to address Psoriatic Arthritis (PsA) and Reproductive Health education to support patients, educators, and clinical teams. Its contents are solely the responsibility of the authors and do not necessarily reflect the official views of Pfizer, Inc.